Altravax, Inc. announced today that it has been awarded two Advanced Technology Small Business Innovation Research grants from the NIH’s National Institute of Allergy and Infectious Diseases for research on vaccines to prevent infection by dengue virus and to treat chronic hepatitis B. Each of these viruses is a global problem and the focus of Altravax’s two lead commercial programs.
“These awards further validate the strength of our vaccine technology,” said Michael Chambers, interim CEO of Altravax. Chambers noted Altravax has received over $4.5 million in non-dilutive funding in recent months, which will be instrumental in bringing these critical products closer to market.